The stock of EXACT Sciences Corporation (NASDAQ:EXAS) is a huge mover today! The stock increased 3.85% or $0.57 on November 23, hitting $15.36. About 1.64 million shares traded hands. EXACT Sciences Corporation (NASDAQ:EXAS) has risen 95.42% since April 22, 2016 and is uptrending. It has outperformed by 90.01% the S&P500.
The move comes after 9 months positive chart setup for the $1.64 billion company. It was reported on Nov, 24 by Barchart.com. We have $16.59 PT which if reached, will make NASDAQ:EXAS worth $131.20 million more.
Analysts await EXACT Sciences Corporation (NASDAQ:EXAS) to report earnings on February, 22. They expect $-0.42 EPS, down 2.44% or $0.01 from last year’s $-0.41 per share. After $-0.36 actual EPS reported by EXACT Sciences Corporation for the previous quarter, Wall Street now forecasts 16.67% negative EPS growth.
EXACT Sciences Corporation (NASDAQ:EXAS) Ratings Coverage
Out of 13 analysts covering EXACT Sciences (NASDAQ:EXAS), 5 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 38% are positive. EXACT Sciences has been the topic of 27 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by BTIG Research on Friday, December 18. The rating was maintained by Goldman Sachs on Monday, August 15 with “Neutral”. The company was maintained on Friday, October 30 by Roth Capital. Empire maintained EXACT Sciences Corporation (NASDAQ:EXAS) on Friday, February 26 with “Sell” rating. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given on Tuesday, October 6 by Roth Capital. The stock has “Buy” rating given by Lake Street on Friday, July 24. The firm has “Buy” rating given on Friday, October 30 by TH Capital. The rating was maintained by Jefferies with “Buy” on Thursday, February 25. The firm earned “Neutral” rating on Thursday, February 25 by Roth Capital. The firm has “Buy” rating given on Wednesday, October 7 by Canaccord Genuity.
According to Zacks Investment Research, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.”
Insitutional Activity: The institutional sentiment increased to 1.48 in Q2 2016. Its up 0.06, from 1.42 in 2016Q1. The ratio is positive, as 18 funds sold all EXACT Sciences Corporation shares owned while 41 reduced positions. 30 funds bought stakes while 54 increased positions. They now own 87.89 million shares or 11.45% more from 78.86 million shares in 2016Q1.
Cubist Systematic Strategies Ltd Limited Liability Company reported 105,958 shares or 0.08% of all its holdings. Tiverton Asset Ltd Llc last reported 0.9% of its portfolio in the stock. Blackrock has 0% invested in the company for 9,547 shares. Oxbow Advsr Limited Liability Corporation holds 10,000 shares or 0.02% of its portfolio. Mycio Wealth Ptnrs Limited Liability Corporation has 0% invested in the company for 216 shares. Woodmont Invest Counsel Ltd Liability Com reported 32,144 shares or 0.12% of all its holdings. Moreover, Retail Bank Of Montreal Can has 0% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 16,758 shares. Stifel Finance Corp reported 20,515 shares or 0% of all its holdings. The Ontario – Canada-based Mackenzie has invested 0.05% in EXACT Sciences Corporation (NASDAQ:EXAS). The Massachusetts-based Adage Capital Prtn Gru Lc has invested 0.01% in EXACT Sciences Corporation (NASDAQ:EXAS). Fil has invested 0.04% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS). Moreover, Fmr Limited Liability has 0% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 2.38M shares. The Minnesota-based Ameriprise Incorporated has invested 0% in EXACT Sciences Corporation (NASDAQ:EXAS). Legal & General Public Ltd Co reported 21,166 shares or 0% of all its holdings. Zevenbergen Cap Investments Lc reported 2.73 million shares or 1.57% of all its holdings.
Insider Transactions: Since July 25, 2016, the stock had 2 insider buys, and 6 selling transactions for $25.84 million net activity. Zanotti Katherine S had bought 3,380 shares worth $60,613. The insider LIDGARD GRAHAM PETER sold 7,383 shares worth $109,416. Another trade for 5,000 shares valued at $90,500 was made by Sterling Lionel on Thursday, September 1. 600,000 shares were sold by Conroy Kevin T, worth $10.48M. The insider COWARD D SCOTT sold 1,701 shares worth $30,584. ARORA MANEESH sold $109,060 worth of EXACT Sciences Corporation (NASDAQ:EXAS) on Monday, July 25.
More important recent EXACT Sciences Corporation (NASDAQ:EXAS) news were published by: Fool.com which released: “1 Sentence in Exact Sciences Corporation’s Q3 Report Cost It 16% in October” on November 07, 2016, also Fool.com published article titled: “Exact Sciences Corp. Gets a Better Balance Sheet”, Fool.com published: “Here’s Why Exact Sciences Corporation’s Stock Is Dropping Today” on October 26, 2016. More interesting news about EXACT Sciences Corporation (NASDAQ:EXAS) was released by: Prnewswire.com and their article: “Exact Sciences Appoints Jeff Elliott Chief Financial Officer” with publication date: November 08, 2016.
EXAS Company Profile
Exact Sciences Corporation, incorporated on February 10, 1995, is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. The Firm has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The Company’s Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test (FIT). The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.